Isofol Medical (Sweden) Performance
| ISOFOL Stock | SEK 2.12 0.05 2.30% |
The company retains a Market Volatility (i.e., Beta) of 1.21, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Isofol Medical will likely underperform. At this point, Isofol Medical AB has a negative expected return of -0.81%. Please make sure to check out Isofol Medical's jensen alpha, skewness, as well as the relationship between the Skewness and day median price , to decide if Isofol Medical AB performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Isofol Medical AB has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in March 2025. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
| Begin Period Cash Flow | 116.4 M |
Isofol |
Isofol Medical Relative Risk vs. Return Landscape
If you would invest 367.00 in Isofol Medical AB on November 2, 2024 and sell it today you would lose (155.00) from holding Isofol Medical AB or give up 42.23% of portfolio value over 90 days. Isofol Medical AB is generating negative expected returns and assumes 5.1422% volatility on return distribution over the 90 days horizon. Simply put, 45% of stocks are less volatile than Isofol, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Isofol Medical Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Isofol Medical's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Isofol Medical AB, and traders can use it to determine the average amount a Isofol Medical's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1581
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | ISOFOL |
Estimated Market Risk
| 5.14 actual daily | 45 55% of assets are more volatile |
Expected Return
| -0.81 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.16 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Isofol Medical is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Isofol Medical by adding Isofol Medical to a well-diversified portfolio.
Isofol Medical Fundamentals Growth
Isofol Stock prices reflect investors' perceptions of the future prospects and financial health of Isofol Medical, and Isofol Medical fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Isofol Stock performance.
| Return On Equity | -0.69 | |||
| Return On Asset | -0.36 | |||
| Operating Margin | (13.09) % | |||
| Current Valuation | (42.41 M) | |||
| Shares Outstanding | 161.52 M | |||
| Price To Book | 0.65 X | |||
| Price To Sales | 7.45 X | |||
| Revenue | 22.41 M | |||
| EBITDA | (198.49 M) | |||
| Cash And Equivalents | 379.45 M | |||
| Cash Per Share | 0.93 X | |||
| Total Debt | 110 K | |||
| Debt To Equity | 0.05 % | |||
| Book Value Per Share | 1.14 X | |||
| Cash Flow From Operations | (188.43 M) | |||
| Earnings Per Share | (1.42) X | |||
| Total Asset | 401.36 M | |||
About Isofol Medical Performance
By analyzing Isofol Medical's fundamental ratios, stakeholders can gain valuable insights into Isofol Medical's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Isofol Medical has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Isofol Medical has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Isofol Medical AB , a clinical stage biotech company, develops, commercializes, and sells oncology drugs in Sweden and internationally. The company was incorporated in 2008 and is headquartered in Gothenburg, Sweden. Isofol Medical operates under Biotechnology classification in Sweden and is traded on Stockholm Stock Exchange. It employs 12 people.Things to note about Isofol Medical AB performance evaluation
Checking the ongoing alerts about Isofol Medical for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Isofol Medical AB help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Isofol Medical AB generated a negative expected return over the last 90 days | |
| Isofol Medical AB has high historical volatility and very poor performance | |
| Isofol Medical AB has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 22.41 M. Net Loss for the year was (200.25 M) with loss before overhead, payroll, taxes, and interest of (174.31 M). | |
| Isofol Medical AB has accumulated about 379.45 M in cash with (188.43 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.93. | |
| Roughly 26.0% of the company shares are held by company insiders |
- Analyzing Isofol Medical's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Isofol Medical's stock is overvalued or undervalued compared to its peers.
- Examining Isofol Medical's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Isofol Medical's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Isofol Medical's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Isofol Medical's stock. These opinions can provide insight into Isofol Medical's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Isofol Stock analysis
When running Isofol Medical's price analysis, check to measure Isofol Medical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Isofol Medical is operating at the current time. Most of Isofol Medical's value examination focuses on studying past and present price action to predict the probability of Isofol Medical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Isofol Medical's price. Additionally, you may evaluate how the addition of Isofol Medical to your portfolios can decrease your overall portfolio volatility.
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets |